title: Immunogenicity of Haemophilus b conjugate vaccine (meningococcal protein conjugate) in children with prior invasive Haemophilus influenzae type b disease.
abstract: Children younger than 2 years of age with previous invasive Haemophilus influenzae (Hib) type b disease may not develop protective antibodies to antigens of Hib and may be at risk of developing a second episode of Hib disease. Twenty-three children with prior Hib disease were immunized with Haemophilus b conjugate vaccine (meningococcal protein conjugate). Children 12 to 24 months of age were given one dose of vaccine and children younger than 12 months of age were given 2 doses 2 months apart. Antibody to the polysaccharide capsule of Hib (PRP) was measured by radioimmunoassay. Eighteen children had preimmunization serum antibody concentrations less than 0.150 micrograms/ml. All 18 children responded with greater than 0.150 micrograms/ml of antibody after a single dose of vaccine. Only 1 of the 23 children had a preimmunization serum antibody concentration greater than 1.000 micrograms/ml. Seventeen children ultimately responded with greater than 1.000 micrograms/ml of antibody (P less than 0.0001), concentrations of antibody thought to correlate with protection. Haemophilus b conjugate vaccine (meningococcal protein conjugate) is immunogenic in children with invasive Hib disease. Children younger than 2 years of age with invasive Hib disease should be subsequently immunized with a Hib conjugate vaccine.
authors.affiliation: Department of Pediatrics, Duke University Medical Center, Durham, NC 27710.
authors.forename: E B
authors.initials: EB
authors.lastname: Walter
authors.forename: M V
authors.initials: MV
authors.lastname: Moggio
authors.forename: R P
authors.initials: RP
authors.lastname: Drucker
authors.forename: C M
authors.initials: CM
authors.lastname: Wilfert
mesh_terms: D000367:Age Factors; D000907:Antibodies, Bacterial / Q000097:blood; D001425:Bacterial Outer Membrane Proteins / Q000009:adverse effects / Q000276:immunology*; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D002675:Child, Preschool; D005260:Female; D006192:Haemophilus Infections / Q000276:immunology*; D018073:Haemophilus Vaccines; D006193:Haemophilus influenzae / Q000276:immunology; D006801:Humans; D007223:Infant; D008297:Male; D011135:Polysaccharides, Bacterial / Q000009:adverse effects / Q000276:immunology*; D014611:Vaccination; D014614:Vaccines, Synthetic
chemical_list: D000907:Antibodies, Bacterial; D001425:Bacterial Outer Membrane Proteins; D001428:Bacterial Vaccines; D018073:Haemophilus Vaccines; C061964:Haemophilus influenzae-type b polysaccharide-Neisseria meningitidis outer membrane protein conjugate vaccine; D011135:Polysaccharides, Bacterial; D014614:Vaccines, Synthetic